Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology ...

MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated ...

MCAS refers to a group of disorders characterized by multisystem symptoms resulting from the accumulation of altered mast cells and/or abnormal mast cell mediator release, causing repeated ...

However, there may still be a suspicion for a clonal mast cell disorder, although it may not be as strong ... by which time your patient’s symptoms have typically resolved. This makes tryptase a ...

Sanofi S.A. (Paris, France) and Blueprint Medicines Corp. (Blueprint), a U.S.-based, publicly traded biopharmaceutical company specializing in systemic ...

THANKS FOR HAVING ME. OKAY, SO THIS CONDITION, IT’S CALLED PREMENSTRUAL DYSPHORIC DISORDER, PMDD, THE SYMPTOMS, THEY SOUND REALLY SCARY. SO DO WE KNOW THE CAUSE? SO WHAT WE THINK IS THE CAUSE IS ...

We had previously suggested that a threshold level of mast cell content (tryptase, chymase and so on) exists [15] above which it can provoke coronary artery spasm and/or plaque erosion or rupture.

If you often feel groggy even after 7–8 hours of sleep, it may signal poor sleep quality or interrupted sleep cycles Uncomfortable tingling or twitching in the legs at night could indicate ...